FDA permitted marketing of first SARS-CoV-2 diagnostic test using traditional premarket review process
On Mar. 17, 2021, the FDA granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic…
Altasciences partnered with NRC of Canada to qualify quantitative serological assay for detection of SARS-CoV-2 IgG antibodies
On Mar. 17, 2021, Altasciences working with the National Research Council of Canada (NRC), announced that it had…
Biden administration announced investment of mre than $12 billion to expand COVID-19 testing
On Mar. 17, 2021, the U.S. Department of Health and Human Services (HHS) announced the investment of $10…
Roche launched SARS-CoV-2 variant test to help monitor emerging coronavirus mutations
On Mar. 16, 2021, Roche announced the launch of the cobasﾮ SARS-CoV-2 Variant Set 1 Test to detect…
AstraZeneca announced supplying the U.S. with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442
On Mar. 16, 2021, AstraZeneca announced it had modified an existing agreement with the US Government to supply…
TGen study predicted changing Lyme disease habitat across the West Coast
On Mar. 16, 2021, TGen announced a study that suggested ecosystems suitable for harboring ticks that carry debilitating…
Military researchers gained new insights into brain injuries
On Mar. 16, 2021, U.S. military researchers announced they had found that headache, dizziness and cognitive dysfunction occur…
Apabetalone treatment prevented COVID-19 infection of human lung cells
On Mar. 15, 2021, Resverlogix announced the publishing of a new article titled: ﾓBromodomain and extraterminal protein inhibitor,…
ImmunityBio announced positive interim phase I safety data of hAd5 T-cell COVID-19 vaccine candidate
On Mar. 15, 2021, ImmunityBio announced it had met the safety requirements for the first 12 participants in…
Altimmuneﾒs single dose, intranasal COVID-19 vaccine candidate prevented SARS-CoV-2-induced disease
On Mar. 15, 2021, Altimmune announced additional preclinical data for its single dose intranasal COVID-19 vaccine candidate, AdCOVID….
Fulgent Genetics awarded contract from CDC to study variants of COVID-19 virus
On Mar. 15, 2021, Fulgent Genetics announced that the U.S. Centers for Disease Control and Prevention had awarded…
WHO added Janssen vaccine to list of safe and effective emergency tools against COVID-19
On Mar. 12, 2021, the WHO listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for…
Johnson & Johnson single-shot COVID-19 vaccine granted Emergency Use Listing by the WHO
On Mar. 12, 2021, Johnson & Johnson announced that the World Health Organization (WHO) had issued Emergency Use…
Abbott announced Pandemic Defense Coalition to help prevent future pandemics
On Mar. 11, 2021, Abbott announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific…
Rigel announced completion of patient enrollment for phase 2 trial of fostamatinib in hospitalized COVID-19 patients
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
Johnson & Johnson announced single-shot COVID-19 vaccine candidate received positive CHMP opinion
On Mar. 11, 2021, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP)…
Real-world evidence confirmed high effectiveness of Pfizer-BioNTech COVID-19 vaccine
On Mar. 11, 2021, the Israel Ministry of Health (MOH), Pfizer and BioNTech announced real-world evidence demonstrating dramatically…
The FDA granted Department of Veterans Affairs first ever compassionate use for 3D-printed hearing device
On Mar. 11, 2021, the Department of Veterans Affairs (VA) announced that it had received compassionate use approval…
TGen launched COVID-19 study with Arizona dog and cat owners
On Mar. 10, 2021, TGen, an affiliate of City of Hope, announced the start of a scientific study…
CEPI and VBI Vaccines collaborated to advance vaccine candidates against COVID-19 variants
On Mar. 10, 2021, CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines announced a partnership to…
Thermo Fisher Scientific announced $600 million in capital investments to expand its bioprocessing production
On Mar. 10, 2021, Thermo Fisher Scientific announced more than $600 million in capital investments to expand its…
NIH scientists used human cerebral organoid to test drug for deadly brain disease
On Mar. 9, 2021, the NIH announced that approximately two years after establishing a human cerebral organoid system…
Agilent completed CE-IVD registration of qRT-PCR In vitro diagnostic kit for SARS-CoV-2 RNA detection
On Mar. 9, 2021, Agilent Technologies announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 9, 2021, NanoViricides announced that NV-CoV-2 and NV-CoV-2-R were found to be highly effective against a…
Oragenics announced Material Transfer Agreement with Biodextris for mucosal adjuvant for intranasal COVID-19 vaccine
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
VBI Vaccines announced enrollment in adaptive phase 1/2 study of prophylactic COVID-19 vaccine candidate
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
AIM ImmunoTech announced first healthy subjects dosed in phase 1 intranasal Ampligen clinical study
On Mar. 8, 2021, AIM ImmunoTech announced that it had dosed the first healthy subjects in its Phase…
Abivax stopped phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk…